Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.

[1]  P. Groeneveld,et al.  Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US , 2021, JAMA network open.

[2]  Samuel T. Savitz,et al.  Contemporary Reevaluation of Race and Ethnicity With Outcomes in Heart Failure , 2021, Journal of the American Heart Association.

[3]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[4]  S. Solomon,et al.  Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan , 2020, Circulation. Heart failure.

[5]  E. Braunwald,et al.  Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. , 2020, JACC. Heart failure.

[6]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[7]  A. Nayak,et al.  Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients , 2020, Circulation. Heart failure.

[8]  Maria R. Shirey,et al.  Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association. , 2020, Circulation.

[9]  J. H. Patterson,et al.  Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). , 2019, The American journal of cardiology.

[10]  James R. Powell,et al.  Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis , 2019, Diabetes, obesity & metabolism.

[11]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[12]  J. Izzo,et al.  Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension , 2019, Circulation.

[13]  Jennifer Kim,et al.  A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans , 2019, Therapeutic advances in cardiovascular disease.

[14]  J. Spertus,et al.  Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure , 2018, JACC. Heart failure.

[15]  Kevin L. Thomas,et al.  Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction , 2018, American heart journal.

[16]  G. Fonarow,et al.  Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. , 2008, Journal of the American College of Cardiology.

[17]  S. Yusuf,et al.  Racial differences in outcome and treatment effect in congestive heart failure. , 2005, American heart journal.

[18]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[19]  S. Goldstein.  Beta Blocker Therapy in African American Patients with Heart Failure , 2004, Heart Failure Reviews.

[20]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[21]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[22]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[23]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.